NeuroMetrix Inc. (NASDAQ:NURO) is scheduled to post its Q316 quarterly earnings results on Thursday, October 20th. Analysts expect NeuroMetrix to post earnings of ($0.82) per share and revenue of $3.01 million for the quarter.
Shares of NeuroMetrix Inc. (NASDAQ:NURO) opened at 1.50 on Wednesday. The company’s market capitalization is $7.68 million. NeuroMetrix Inc. has a 52 week low of $1.35 and a 52 week high of $3.56. The company’s 50 day moving average is $1.50 and its 200-day moving average is $1.65.
A number of analysts have recently issued reports on NURO shares. Zacks Investment Research cut NeuroMetrix from a “hold” rating to a “sell” rating in a research report on Wednesday, August 31st. Rodman & Renshaw set a $4.50 price objective on NeuroMetrix and gave the company a “buy” rating in a research report on Sunday, September 4th. Finally, HC Wainwright set a $4.50 price objective on NeuroMetrix and gave the company a “buy” rating in a research report on Thursday, September 15th.
NeuroMetrix, Inc (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets.
Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.